Lighting up the fire in cold tumors to improve cancer immunotherapy by blocking the activity of the autophagy-related protein PIK3C3/VPS34
Bassam Janji, Meriem Hasmim, Santiago Parpal, Angelo De Milito, Guy Berchem, Muhammad Zaeem Noman
Abstract
T cells into the tumor bed. Furthermore, we reported that combining pharmacological inhibitors of PIK3C3/VPS34 improves the therapeutic benefit of anti-PD-1/PD-L1 immunotherapy. Our results provided the proof-of-concept to set-up innovative clinical trials for cold ICB-unresponsive tumors by combining PIK3C3/VPS34 inhibitors with anti-PDCD1/PD-1 and anti-CD274/PD-L1.
Topics & Concepts
AutophagyImmune systemImmune checkpointImmunotherapyBlockadeCancer researchImmunogenic cell deathBiologyMelanomaTumor microenvironmentCancer immunotherapyCD8CancerImmunologyReceptorGeneticsBiochemistryApoptosisAutophagy in Disease and TherapyImmune Cell Function and InteractionImmune cells in cancer